NCT02737891View on ClinicalTrials.gov

Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

March 31, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Tesofensine/Metoprolol

Tesofensine 0.5 mg + Metoprolol 100 mg

DRUG

Placebo

Trial Locations (1)

D-41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Saniona
All Listed Sponsors
collaborator

Profil Institut für Stoffwechselforschung GmbH

INDUSTRY

lead

Saniona

INDUSTRY

NCT02737891 - Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter